Pharma News and Headlines
Pharma News and Headlines
The 2026 Conference on Retroviruses and Opportunistic Infections (CROI) highlighted major HIV research breakthroughs while underscoring persistent funding shortfalls. Experts praised advances in antiretroviral therapy, emerging adjunct treatments, and global advocacy, yet warned that reduced U.S. support could limit access to life‑saving medicines. Clinical leaders emphasized integrating hepatitis B screening and novel anti‑inflammatory agents like GLP‑1 agonists into care pathways. The event concluded with a call for tailored global guidelines and sustained investment to translate scientific progress into broader public‑health impact.
Scientists at Scripps Research have engineered a native‑like, stabilized version of the hepatitis C virus E1E2 glycoprotein complex and displayed it on self‑assembling protein nanoparticles (SApNPs). The nanoparticle vaccine candidate elicited strong, virus‑specific antibody responses in animal models. This breakthrough overcomes...
Five interdisciplinary teams will receive up to £20 million each from the UK‑US Cancer Grand Challenges, adding £100 million to the programme and raising total investment to £465 million since 2016. The five projects, spanning 34 institutions in nine countries, target unconventional angles...
Moderna agreed to settle Roivant's patent claims for up to $2.25 billion, paying $950 million upfront and a contingent $1.3 billion if its liability‑shifting strategy fails. The deal averts a Delaware jury trial that many analysts feared would be costly and damaging. Simultaneously,...
The FDA issued a final rule establishing a uniform 12‑digit National Drug Code (NDC) format effective March 7, 2033, replacing the current 10‑digit variants. A seven‑year window (2026‑2033) gives manufacturers, distributors, pharmacies and payors time to upgrade systems and labeling, followed by...
The FDA issued a complete‑response letter to UniQure, requiring a randomized, double‑blind, sham‑surgery Phase 3 trial for its Huntington’s disease gene therapy, and similarly rejected REGENXBIO’s Hunter syndrome candidate over study design flaws. Regulatory experts warned that the agency’s decision‑making appears...
Theolytics, an Oxford‑based biotech, secured an €8 million non‑dilutive Horizon Europe grant to fund its phase 2 OCTOPOD‑IV expansion trial of THEO‑260, a novel oncolytic therapy for advanced ovarian cancer. The grant, awarded after a rigorous review, will finance the phase 2a portion...
EveryONE Medicines announced its shutdown just a week after the FDA released draft guidance for its new bespoke pathway targeting personalized genetic therapies. The guidance requires each individualized drug to be submitted as a separate application, a burden that the...
Aspire Biopharma has teamed with particle‑engineering specialist Microsize to develop a sublingual powder formulation of alprazolam, aiming for faster anxiety relief than traditional tablets. The partnership leverages Microsize’s micronisation expertise and Pace’s excipient compatibility and stability services to accelerate development....
Extracellular vesicles (EVs) are emerging as a versatile platform for regenerative medicine and targeted drug delivery. Researchers highlight their ability to transfer proteins, RNA, and lipids between cells, mimicking natural signaling pathways. Recent advances in isolation, engineering, and loading techniques...
The UK government announced nearly £48 million in equipment funding to accelerate commercial clinical trials across the NHS. The money will equip 51 NHS trusts and 79 primary‑care organisations with diagnostic tools, scanners and mobile research vans, with 60 % directed to...
Pharmaceutical firms are accelerating onshoring efforts, with more than $270 billion pledged for U.S. manufacturing since early 2025 and 80% of global producers weighing domestic or near‑shore options. Legislative moves such as the BIOSECURE Act and incentives like BARDA Project NextGen are...
Hua Medicine announced that its glucokinase activator dorzagliatin, marketed as MYHOMSIS®, received marketing approval from Hong Kong’s Department of Health under the “1+” regulatory pathway. The drug, the world’s first‑in‑class GKA, targets the root cause of glucose dysregulation in Type 2 diabetes...
A large retrospective study of over 600,000 U.S. veterans found that patients prescribed GLP-1 receptor agonists for diabetes were 14% less likely to develop new substance-use disorders compared with those on SGLT-2 inhibitors. The analysis also showed 30% fewer drug-related...
Merck’s Keytruda remained pharma’s top‑selling drug in 2025, generating $31.7 billion and a 7 % year‑on‑year increase. However, the combined sales of GLP‑1 franchises—Eli Lilly’s tirzepatide line and Novo Nordisk’s semaglutide portfolio—totaled over $36 billion, overtaking Keytruda for the first time. The GLP‑1 market is...
A new Nature study sequenced the whole genomes of 1,364 breast cancers and linked the data to transcriptomics and real‑world treatment outcomes. The analysis showed that genome‑wide signatures such as homologous recombination deficiency, intratumoral heterogeneity, and copy‑number instability correlate with...
EyePoint reported Q4 2025 results, highlighting rapid enrollment of over 900 patients in two pivotal wet AMD Phase 3 trials (Lugano and LUCHIA) with top‑line data expected mid‑2026. The company also initiated Phase 3 DME studies (COMO and CAPREIT) slated for first...
Karyopharm Therapeutics reported Q4 2025 total revenue of $34.1 million, an 11.8% year‑over‑year increase, driven primarily by XPOVIO net product revenue of $32.1 million. The company trimmed R&D and SG&A expenses, improving operating performance by roughly 43% quarter‑over‑quarter, yet posted a GAAP...
Verastem reported $1.7 million in COPIKTRA net revenue for Q1 2019, a 38% increase over the prior quarter, and achieved reimbursement coverage with more than 92% of targeted health plans. Clinical updates highlighted the Phase 3 DUO trial, which showed...
Niagen Bioscience reported Q2 2025 revenue of $31.1 million, a 37% year‑over‑year increase, and lifted full‑year revenue guidance to 22‑27%. Gross margin improved to 65% driven by a higher‑margin sales mix and inventory efficiencies. The company expanded its Niagen Plus clinic...
![[Comment] Considerations for Improving Non-Inferiority Trials](/cdn-cgi/image/width=1200,quality=75,format=auto,fit=cover/https://hixhlmpcokxhartfkpyi.supabase.co/storage/v1/object/public/images/thumbnails/0f1a72bb75d13d20256f6082d5abd222.webp)
Non‑inferiority trials are increasingly employed to evaluate new therapies that may offer advantages beyond efficacy, such as safety or convenience. However, their design and analysis present unique methodological challenges that can compromise study validity. The commentary outlines essential considerations, including...
Sino Biopharm’s subsidiary Chia Tai Tianqing Pharmaceutical Group has signed an exclusive global licensing deal with Sanofi for its blood‑cancer drug rovadicitinib. The agreement provides Sanofi with worldwide rights to develop, manufacture and commercialize the oral JAK/ROCK inhibitor, and includes...
The Therapeutic Goods Administration (TGA) has launched two concept papers for public consultation, proposing revisions to PIC/S GMP Annex 6 for medicinal gases and Annex 15 for qualification and validation processes. The Annex 6 update seeks to reflect modern manufacturing technologies and computerized...
The FDA has approved the first generic version of Flovent HFA, a fluticasone propionate inhalation aerosol delivering 44 µg per actuation for asthma maintenance in patients aged four and older. The generic, produced by Glenmark Specialty SA, matches the brand’s safety and efficacy...
Oculis Holding AG reported a transformative 2025, highlighted by a $268.7 million cash position that extends its runway to 2029 and a $210 million equity raise. The company secured FDA Breakthrough Therapy designation for Privosegtor, its neuro‑protective candidate for optic neuritis, and...
Virginia lawmakers are proposing a prescription‑drug affordability board that will use Medicare’s annually negotiated drug list as its benchmark. The board would also impose upper payment limits, creating a ceiling on what insurers pay for those medicines. This strategy would...
A phase‑1 pilot of low‑dose intralesional cemiplimab in early‑stage cutaneous squamous cell carcinoma (CSCC) demonstrated rapid tumor regression with visual objective response rates of 66.7%–75% and pathologic complete responses of 58.3%–66.7%. Safety was favorable, with no grade ≥ 3 events and minimal...
The FDA granted accelerated approval to navepegritide (Yuviwel), a once‑weekly CNP prodrug, for children aged two years and older with achondroplasia and open growth plates. In the phase 2b ApproaCH trial, the drug raised annualized growth velocity to 5.89 cm/year, a 1.49 cm/year...
New post‑hoc analyses of the phase 3 STOP‑HS1 and STOP‑HS2 trials show that oral povorcitinib, a selective JAK1 inhibitor, delivers rapid, high‑threshold lesion clearance in patients with severe hidradenitis suppurativa. In the 75 mg arm, up to 57% of participants achieved complete...
Kyowa Kirin announced it will cease all clinical trials of rocatinlimab, an anti‑OX40 antibody once touted as a potential eczema blockbuster, after a safety review identified emerging malignancy signals. The review, conducted with former partner Amgen, uncovered a confirmed and...
Real‑world evidence from Duke’s PRECISION platform shows Pluvicto (Lu‑177 vipivotide tetraxetan) delivers a median progression‑free survival of 13.5 months in PSMA‑positive metastatic castration‑resistant prostate cancer (mCRPC) after androgen‑receptor pathway inhibitor (ARPI) therapy, matching the pivotal PSMAfore trial. Patients who received Pluvicto...
The FDA’s Drug Competition Action Plan (DCAP) continues to drive generic drug competition by streamlining standards for complex products, closing loopholes that allow brand‑name companies to delay approvals, and improving the overall ANDA review process. Aligned with GDUFA III, the plan...
U.S. pharmaceutical tariffs on EU imports have risen to 15% after a brief 10% measure, reviving trade tensions despite a prior MFN deal. Europe is pursuing alternative markets, notably a new EU‑India free‑trade agreement that could eliminate up to 11%...
New integrated safety data from 20 trials confirm that ruxolitinib 1.5% cream delivers a low incidence of serious infections, cardiovascular events, thromboembolic events, and malignancies across atopic dermatitis, vitiligo and other inflammatory skin conditions. A phase 3b trial in adults with...
The FDA has published a batch of newly added guidance documents, spanning drug exclusivity, post‑approval safety reporting, real‑world data studies, Bayesian trial methods, and patient‑preference research. Ten documents are highlighted, with six in draft form and four finalized, dated between...
A MEDSIR‑hosted webinar titled “The Future is Collaborative: Transforming Clinical Trials” examined how collaborative‑initiated trials and investigator‑initiated trials (IITs) are reshaping oncology research. Speakers Dr. Javier Cortés and Dr. Antonio Llombart‑Cussac, both leading breast‑cancer oncologists, discussed their roles in recent...
A team of researchers proposes "pharmaceutical superintelligence," an AI‑driven pipeline that can turn a plain‑language request into a preclinical drug candidate and even outline clinical trial plans. The framework stitches together generative chemistry models, multi‑agent reasoning, and robotic labs into...
The FDA issued a warning letter to MaxLife Technologies for false and misleading claims on its website about compounded semaglutide and tirzepatide products. The company labeled the drugs as “generic compounded medication” and implied FDA approval and that MaxLife was...
Researchers at Karolinska Institutet reported that phosphorothioate antisense oligonucleotides (ASOs) directly bind key DNA‑repair enzymes, forming nuclear condensates that trigger a false DNA‑damage response. The effect was observed at concentrations commonly used in laboratory assays, though clinical doses reach lower...
An international panel of 147 oncology leaders, including Prof. John Bridgewater, issued a consensus calling for sweeping reforms in the diagnosis, treatment, and research of cholangiocarcinoma (bile duct cancer). The disease remains deadly, with three‑quarters of patients dying within a...
Philadelphia’s biotech ecosystem, long known for CAR‑T breakthroughs, is diversifying into obesity, metabolic disease, gene editing, and solid‑tumor immunotherapies. Nine local companies illustrate this shift, from Alveus Therapeutics’ $197 million Series A obesity program to Cabaletta Bio’s autologous CD19 CAR‑T for autoimmune...
February 2026 saw a surge of biosimilar activity, with key regulatory approvals for products such as Sandoz Enzeevu (Eylea), Accord Filkri (Neupogen), and STADA Gotenfia (Simponi) across the US, Canada and the EU. Companies forged new licensing and commercialization deals that extend biosimilar...
Quell Therapeutics has launched the phase 1/2 CHILL trial of its autologous CAR‑Treg therapy QEL‑005 in rheumatoid arthritis and systemic sclerosis, after pausing the liver‑transplant program QEL‑001. The multi‑center study will enroll patients in the UK, Germany and Spain, with read‑out...
Boehringer Ingelheim has terminated its metabolic dysfunction‑associated steatohepatitis (MASH) collaboration with OSE Immunotherapeutics after an exploratory Phase 2 trial failed to meet its primary endpoint. The original 2018 deal included a €15 million upfront payment and up to €1.1 billion in milestone potential,...
Lynk Pharmaceuticals announced topline Phase III data for its oral JAK inhibitor zemprocitinib in 356 patients with moderate‑to‑severe atopic dermatitis. Both the 12 mg and 24 mg doses met the co‑primary endpoints at week 16, delivering 38‑46 percentage‑point improvements in EASI‑75 and roughly 30 percentage‑point gains...
The GAO report reveals that, despite a conditional approval pathway introduced in 2004 and expanded in 2018, FDA‑approved animal drugs for minor species and niche uses remain scarce. From FY2018 through FY2025, only 13 drugs received conditional approval, all targeting...
The FDA concluded that UniQure’s experimental gene therapy for Huntington’s disease has not demonstrated therapeutic benefit based on existing clinical data. Reviewers said they are not persuaded by the evidence, prompting the agency to block the company from submitting a...
Innovent’s pirtobrutinib, marketed as Jaypirca, received Chinese NMPA approval for adults with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma who have undergone at least one prior therapy, including a BTK inhibitor. The decision follows the phase‑III BRUIN CLL‑321 trial,...
The U.S. Centers for Medicare & Medicaid Services (CMS) has pushed back the deadline for manufacturers to join its GENEROUS pilot, extending the initial cut‑off to April 30 while keeping the final deadline at June 30. The voluntary program applies a Most‑Favoured...
Merck and Eisai disclosed Phase III LITESPARK-011 results showing that the oral combination of Welireg (belzutifan) and Lenvima (lenvatinib) outperformed cabozantinib in 747 patients with advanced renal cell carcinoma who progressed after anti‑PD‑1/PD‑L1 therapy. At a median follow‑up of 29...
